CVS Health Stock (CVS)

XNYS Sideways Alert Compare

Health Care · Fundamental analysis and chart analysis

· How we analyze

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

CVS Health is a major US healthcare company. It runs thousands of pharmacies, the health insurer Aetna and, with Caremark, a pharmacy benefit manager. It also operates doctors’ offices and primary care. As of Oct 13, 2026

Fact sheet (from the annual report) Pharmacies and drugstores · Woonsocket, USA

The group offers health insurance, manages pharmacy benefits, runs stores and clinics and reports in the segments Health Care Benefits and Health Services, among others. Under the Aetna name, the insurance segment offers medical, dental and behavioral health plans as well as plans for the government programs Medicare and Medicaid. Members are insured mainly through employers, government programs or individually; sales run through its own employees as well as brokers, agents and consultants. Under CVS Caremark, the Health Services segment manages pharmacy benefits mainly for employers, insurers, unions and health plans, including mail-order and specialty pharmacies. This segment also includes the Oak Street Health primary care centers for members in the Medicare program as well as Signify Health.

Automatically summarized from SEC annual report (10-K, filed Feb 10, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +1.0%
  • 7 days −9.5%
  • 30 days −13.5%
  • 1 year +6.3%
Day range (last trading day)
−0.2%Price at 10% of the range+1.8%
52-week range
−14.0%Price at 28% of the range+36.9%
Distance from the all-time high
−28.9%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Detected chart patterns

  • Warning pattern Head and shoulders on the daily chart, detected on Nov 4, 2026

Chart patterns with zone, stop and targets

Free account

13 patterns with a zone · 11 Warning patterns · detected in 23 symbols

You see the zone, stop, two targets and the pattern lines in the chart with a free account.

  • Ascending triangle
  • Flag
  • Falling wedge
  • Inverse head and shoulders
  • Cup with handle
  • Range breakout
  • Double bottom
  • Pullback in trend
  • 52-week-high breakout
  • Gap with volume
  • Double top
  • Head and shoulders
  • Descending triangle

Create a free account

Free with an account until Jan 31, 2027: all Premium features, no subscription and no card. Sign up free

Earlier patterns · Past performance, not a forecast

Premium The list of earlier chart patterns of this asset with their outcome is available with a free account.

Chart analysis: trend by timeframe

  1. 1W weekly candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • lower highs and lower lows

    Price below the EMA 20 · below the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles down
    • Close below the SMA 200
    • EMA 20 below the EMA 50
    • lower highs and lower lows

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles mixed
    • Close below the SMA 200
    • EMA 20 below the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Candle from Nov 20, 2026, 19:30

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran weaker than the S&P 500 and weaker than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
weaker
vs. S&P 500 · 6 months
weaker
vs. sector · 3 months
weaker
  • Trend below SMA 200 Price below the 200-day line – below it the long-term trend counts as down; ADX between 20 and 25 – a moderate trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility normal Typical daily range (ATR 14) between 2 and 4% of the price – normal.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran weaker.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 7 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
7 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
5 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 4 of 10 years
  • February: higher in 3 of 10 years
  • March: higher in 4 of 10 years
  • April: higher in 6 of 10 years
  • May: higher in 4 of 10 years
  • June: higher in 6 of 10 years
  • July: higher in 6 of 10 years
  • August: higher in 5 of 10 years
  • September: higher in 6 of 10 years
  • October: higher in 4 of 10 years
  • November (current month): higher in 7 of 10 years
  • December: higher in 4 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January4 of 10
February3 of 10
March4 of 10
April6 of 10
May4 of 10
June6 of 10
July6 of 10
August5 of 10
September6 of 10
October4 of 10
November ●7 of 10
December4 of 10

Through October 2026 (last completed month) · from our daily candles

Opportunity at a glance CVS Health

What does this mean? The card sums up chart patterns, potential to target, risk to stop and supports of CVS Health on the 4H, daily and weekly charts – every figure with its timeframe.

Potential to target 1hidden 4-hour or daily chart
Risk to stop
hidden
Reward/risk
hidden

Remaining potential: moved since detection and still open to target 1 – each in % with timeframe.

Trend 4H mixed 1D down 1W mixed

In favour 0 · Against 1 Points without chart-pattern detail – you see every point with figure and date with a free account

You see all figures, supports, for and against, and similar stocks with a free account. Create a free account

Fundamental analysis

CVS Health · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 10, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 2.3x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.9%
dividend per share, average per year
Coverage by free cash flow
2.3x
covered from 1.0x

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 7
criteria with data met
Revenue per year (5 y)
+8.4%
EPS per year (5 y)
−23.9%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
2 of 7
criteria with data met
Net margin
0.4%
Cash flow ÷ profit
6.16x
backed from 1.0 · 3 years: 2.26x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
mixed
daily candles
down
4-hour candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 2 of 7 met · 1 without data

  • no data: Gross margin above 40% reported cost of revenue does not include the benefit costs (margin more than 15 percentage points above an operating margin below 10%, e.g. health insurers)
  • not met: Operating margin above 15% 1.2%
  • not met: Net margin above 10% 0.4%
  • not met: Return on equity above 15% 2.4%
  • not met: Free cash flow margin above 10% 1.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% 29.7%
Operating margin

1.2% Fiscal year 2025

Rank 18 of 100: higher than 18% of 470 peers (All). weak.

Rank 18 of 100: higher than 18% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

0.4% Fiscal year 2025

Rank 14 of 100: higher than 14% of 584 peers (All). weak.

Rank 12 of 100: higher than 12% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

2.4% Fiscal year 2025

Rank 16 of 100: higher than 16% of 544 peers (All). weak.

Rank 12 of 100: higher than 12% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

0.7% Fiscal year 2025 (total assets at year end)

Rank 16 of 100: higher than 16% of 594 peers (All). weak.

Rank 12 of 100: higher than 12% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

29.7% Fiscal year 2025

Rank 39 of 100: higher than 39% of 595 peers (All). medium.

Rank 29 of 100: higher than 29% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

1.9% Fiscal year 2025

Rank 20 of 100: higher than 20% of 465 peers (All). weak.

Rank 17 of 100: higher than 17% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

7.8B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +7.6%
  • met: Over 5 years, revenue grew by more than 5% per year +8.4%
  • met: Over 10 years, revenue grew by more than 5% per year +10.1%
  • not met: Over 3 years, EPS grew by more than 5% per year −23.8%
  • not met: Over 5 years, EPS grew by more than 5% per year −23.9%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +7.8%
Revenue growth 3 years

+7.6% per year

Rank 58 of 100: higher than 58% of 578 peers (All). medium.

Rank 64 of 100: higher than 64% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+8.4% per year

Rank 48 of 100: higher than 48% of 549 peers (All). medium.

Rank 53 of 100: higher than 53% of 60 peers (Sector). medium.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+10.1% per year

Rank 71 of 100: higher than 71% of 412 peers (All). strong.

Rank 59 of 100: higher than 59% of 50 peers (Sector). medium.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−23.8% per year

Rank 9 of 100: higher than 9% of 437 peers (All). weak.

Rank 6 of 100: higher than 6% of 54 peers (Sector). weak.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−23.9% per year

Rank 2 of 100: higher than 2% of 399 peers (All). weak.

Rank 3 of 100: higher than 3% of 47 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

−11.3% per year

Rank 3 of 100: higher than 3% of 375 peers (All). weak.

Rank 1 of 100: higher than 1% of 46 peers (Sector). weak.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 2.66 USD
  • not met: Payout ratio at most 60% of earnings 191%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +5.9%
  • met: Free cash flow per share covers the dividend 2.3x
  • met: Dividends paid over the last 5 years covered by free cash flow 29% of free cash flow
Payout ratio

191% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+5.9% per year

Rank 40 of 100: higher than 40% of 321 peers (All). medium.

Rank 44 of 100: higher than 44% of 31 peers (Sector). medium.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

2.3x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.80
  • not met: Current assets cover current liabilities 0.84
  • met: Positive equity 75.2B USD
  • met: In 5 years, share count up by at most 5% −3.3%
  • met: Free cash flow positive in the last fiscal year 7.8B USD
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 69 of 100: higher than 69% of 310 peers (All). strong.

Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.80 at fiscal year end

Rank 39 of 100: lower than 39% of 486 peers (All). medium.

Rank 27 of 100: lower than 27% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.84 at fiscal year end

Rank 17 of 100: higher than 17% of 513 peers (All). weak.

Rank 6 of 100: higher than 6% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−3.3% in 5 years

Rank 52 of 100: lower than 52% of 507 peers (All). medium.

Rank 45 of 100: lower than 45% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+8.4% per year), more slowly than the sector median.
  • Light red: Net income (total) shrank over 5 years (−24.4% per year); per share −23.9% per year.
  • Light yellow: Net margin 0.4%, below the sector median (13.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light yellow: Profit in 9 of 10 fiscal years.
  • Light red: Dividend higher than earnings.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 177.5B USD · Net income 5.3B USD · Net margin 3.0%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 184.8B USD · Net income 6.6B USD · Net margin 3.6%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 194.6B USD · Net income −594.0M USD · Net margin −0.3%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 256.8B USD · Net income 6.6B USD · Net margin 2.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 268.7B USD · Net income 7.2B USD · Net margin 2.7%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 292.1B USD · Net income 7.9B USD · Net margin 2.7%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 322.5B USD · Net income 4.1B USD · Net margin 1.3%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 357.8B USD · Net income 8.3B USD · Net margin 2.3%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 372.8B USD · Net income 4.6B USD · Net margin 1.2%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 402.1B USD · Net income 1.8B USD · Net margin 0.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 402.1B USD · Net income 1.8B USD · Net margin 0.4%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +5.4% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.

Revenue 12 months vs. prior 12
+6.7%
12 months: 420.6B USD · Fiscal year 2025: +7.8%
Net margin 12 months
2.6%
Fiscal year 2025: 0.4%
Free cash flow margin 12 months
3.7%
Fiscal year 2025: 1.9%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 402.1B USD + year to date to Sep 30, 2026 314.9B USD − same period a year earlier to Sep 30, 2025 296.4B USD = 420.6B USD
  • Net income: fiscal year to Dec 31, 2025 1.8B USD + year to date to Sep 30, 2026 8.1B USD − same period a year earlier to Sep 30, 2025 −1.2B USD = 11.0B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 10.6B USD + year to date to Sep 30, 2026 15.3B USD − same period a year earlier to Sep 30, 2025 7.2B USD = 18.7B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 2.8B USD + year to date to Sep 30, 2026 2.4B USD − same period a year earlier to Sep 30, 2025 2.0B USD = 3.1B USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 26108.4B+5.4%2.2B2.0%
Apr–Jun 26106.1B+7.3%3.0B2.8%
Jan–Mar 26100.4B+6.2%2.9B2.9%
Oct–Dec 25*105.7B+8.2%2.9B2.8%
Jul–Sep 25102.9B+7.8%−4.0B−3.9%
Apr–Jun 2598.9B+8.4%1.0B1.0%
Jan–Mar 2594.6B+7.0%1.8B1.9%
Oct–Dec 24*97.7B+4.2%1.6B1.7%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is thinly covered.

Cash flow ÷ profit
6.16x
backed from 1.0 · 3 years: 2.26x
Interest coverage
1.5x
well covered from 5 · 3 years: 3.1x
Tax rate
19.1%
for information only · 3 years: 24.5%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 10.6B USD ÷ group profit incl. minority interests 1.7B USD = 6.16x
  • Operating income 4.7B USD ÷ Interest expense 3.1B USD = 1.5x
  • Taxes 408.0M USD ÷ profit before tax 2.1B USD = 19.1%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20256.16x1.5x19.1%
20241.99x2.9x25.4%
20231.60x5.2x25.1%
20223.88x3.4x26.0%
20212.31x5.3x24.2%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years one loss year and no year with lower revenue.

Loss years
1 of 10
net income below zero
Years with lower revenue
0 of 10
revenue below the prior year
Net margin range
3.9 percentage points
from −0.3% to 3.6%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+7.8%0.4%
2024+4.2%1.2%
2023+10.9%2.3%
2022+10.4%1.3%
2021+8.7%2.7%
2020+4.6%2.7%
2019+32.0%2.6%
2018+5.3%−0.3%
2017+4.1%3.6%
2016+15.8%3.0%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Since when has today’s status held?

Check status by fiscal year

Quality: 2 of 7 criteria in every annual report since 2024; Financial strength in fiscal year 2025: 5 of 6 (prior year 4 of 6).

  • Quality 2 of 7 since FY 2024 · before that 3 of 7
  • Growth 5 of 7 since FY 2024 · before that 6 of 6
  • Dividend 6 of 7 since FY 2024 · before that 7 of 7
  • Financial strength 5 of 6 since FY 2025 · before that 4 of 6
More depth
Criteria met by fiscal year (met/with data)
Check20212022202320242025
Quality2/72/73/72/72/7
Growth5/65/76/65/75/7
Dividend7/76/77/76/76/7
Financial strength4/64/64/64/65/6

Fiscal year 2025 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).

Earlier years as of the filing date of their annual report: FY 2024 on Feb 12, 2025, FY 2023 on Feb 7, 2024, FY 2022 on Feb 8, 2023, FY 2021 on Feb 9, 2022.

Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.

As of annual reports 2021–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 1.2 USD operating income and 0.4 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue402.1B USD100.0%
Operating income4.7B USD1.2%
Cost of revenue and operating expenses397.4B USD98.8%
Net income1.8B USD0.4%
Taxes408.0M USD0.1%
Interest & other (net)2.5B USD0.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 5.2% to 1.2%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 16.3% · Operating margin 5.8% · Net margin 3.0%
  2. Fiscal year 2017: Gross margin 15.4% · Operating margin 5.2% · Net margin 3.6%
  3. Fiscal year 2018: Gross margin not available · Operating margin 2.1% · Net margin −0.3%
  4. Fiscal year 2019: Gross margin not available · Operating margin 4.7% · Net margin 2.6%
  5. Fiscal year 2020: Gross margin not available · Operating margin 5.2% · Net margin 2.7%
  6. Fiscal year 2021: Gross margin not available · Operating margin 4.5% · Net margin 2.7%
  7. Fiscal year 2022: Gross margin not available · Operating margin 2.4% · Net margin 1.3%
  8. Fiscal year 2023: Gross margin not available · Operating margin 3.8% · Net margin 2.3%
  9. Fiscal year 2024: Gross margin not available · Operating margin 2.3% · Net margin 1.2%
  10. Fiscal year 2025: Gross margin not available · Operating margin 1.2% · Net margin 0.4%

Returns

Return on equity fell in 5 years from 10.3% to 2.4%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 14.4% · Return on assets 5.6%
  2. Fiscal year 2017: Return on equity 17.6% · Return on assets 7.0%
  3. Fiscal year 2018: Return on equity −1.0% · Return on assets −0.3%
  4. Fiscal year 2019: Return on equity 10.4% · Return on assets 3.0%
  5. Fiscal year 2020: Return on equity 10.3% · Return on assets 3.1%
  6. Fiscal year 2021: Return on equity 10.5% · Return on assets 3.4%
  7. Fiscal year 2022: Return on equity 5.8% · Return on assets 1.8%
  8. Fiscal year 2023: Return on equity 10.9% · Return on assets 3.3%
  9. Fiscal year 2024: Return on equity 6.1% · Return on assets 1.8%
  10. Fiscal year 2025: Return on equity 2.4% · Return on assets 0.7%

Equity and long-term debt

The equity ratio stayed roughly the same in 5 years (29.7%).

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.
  1. Fiscal year 2016: Equity 36.8B USD · Long-term debt 25.7B USD
  2. Fiscal year 2017: Equity 37.7B USD · Long-term debt 25.7B USD
  3. Fiscal year 2018: Equity 58.2B USD · Long-term debt 71.4B USD
  4. Fiscal year 2019: Equity 63.9B USD · Long-term debt 64.7B USD
  5. Fiscal year 2020: Equity 69.4B USD · Long-term debt 59.2B USD
  6. Fiscal year 2021: Equity 75.1B USD · Long-term debt 52.0B USD
  7. Fiscal year 2022: Equity 71.0B USD · Long-term debt 50.5B USD
  8. Fiscal year 2023: Equity 76.5B USD · Long-term debt 58.6B USD
  9. Fiscal year 2024: Equity 75.6B USD · Long-term debt 60.5B USD
  10. Fiscal year 2025: Equity 75.2B USD · Long-term debt 60.5B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 0.91 to 0.84.

Current ratio
  1. Fiscal year 2016: Current ratio 1.18
  2. Fiscal year 2017: Current ratio 1.02
  3. Fiscal year 2018: Current ratio 1.03
  4. Fiscal year 2019: Current ratio 0.94
  5. Fiscal year 2020: Current ratio 0.91
  6. Fiscal year 2021: Current ratio 0.88
  7. Fiscal year 2022: Current ratio 0.94
  8. Fiscal year 2023: Current ratio 0.86
  9. Fiscal year 2024: Current ratio 0.81
  10. Fiscal year 2025: Current ratio 0.84

Cash flow

Free cash flow fell in 5 years from 13.4B USD to 7.8B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 10.1B USD · Capital expenditure 2.2B USD · Free cash flow 7.8B USD
  2. Fiscal year 2017: Operating cash flow 8.0B USD · Capital expenditure 1.9B USD · Free cash flow 6.1B USD
  3. Fiscal year 2018: Operating cash flow 8.9B USD · Capital expenditure 2.0B USD · Free cash flow 6.8B USD
  4. Fiscal year 2019: Operating cash flow 12.8B USD · Capital expenditure 2.5B USD · Free cash flow 10.4B USD
  5. Fiscal year 2020: Operating cash flow 15.9B USD · Capital expenditure 2.4B USD · Free cash flow 13.4B USD
  6. Fiscal year 2021: Operating cash flow 18.3B USD · Capital expenditure 2.5B USD · Free cash flow 15.7B USD
  7. Fiscal year 2022: Operating cash flow 16.2B USD · Capital expenditure 2.7B USD · Free cash flow 13.5B USD
  8. Fiscal year 2023: Operating cash flow 13.4B USD · Capital expenditure 3.0B USD · Free cash flow 10.4B USD
  9. Fiscal year 2024: Operating cash flow 9.1B USD · Capital expenditure 2.8B USD · Free cash flow 6.3B USD
  10. Fiscal year 2025: Operating cash flow 10.6B USD · Capital expenditure 2.8B USD · Free cash flow 7.8B USD

Share count

The share count fell in 5 years by 3.3% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 1.1B
  2. Fiscal year 2017: Diluted share count 1.0B
  3. Fiscal year 2018: Diluted share count 1.0B
  4. Fiscal year 2019: Diluted share count 1.3B
  5. Fiscal year 2020: Diluted share count 1.3B
  6. Fiscal year 2021: Diluted share count 1.3B
  7. Fiscal year 2022: Diluted share count 1.3B
  8. Fiscal year 2023: Diluted share count 1.3B
  9. Fiscal year 2024: Diluted share count 1.3B
  10. Fiscal year 2025: Diluted share count 1.3B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Earnings per share

Earnings per share fell in 5 years from 5.46 USD to 1.39 USD.

CVS USD per share
  1. Fiscal year 2016: CVS 4.90 USD
  2. Fiscal year 2017: CVS 6.44 USD
  3. Fiscal year 2018: CVS −0.57 USD
  4. Fiscal year 2019: CVS 5.08 USD
  5. Fiscal year 2020: CVS 5.46 USD
  6. Fiscal year 2021: CVS 5.95 USD
  7. Fiscal year 2022: CVS 3.14 USD
  8. Fiscal year 2023: CVS 6.47 USD
  9. Fiscal year 2024: CVS 3.66 USD
  10. Fiscal year 2025: CVS 1.39 USD

Revenue

Revenue rose in 5 years from 268.7B USD to 402.1B USD.

CVS in USD
  1. Fiscal year 2016: CVS 177.5B USD
  2. Fiscal year 2017: CVS 184.8B USD
  3. Fiscal year 2018: CVS 194.6B USD
  4. Fiscal year 2019: CVS 256.8B USD
  5. Fiscal year 2020: CVS 268.7B USD
  6. Fiscal year 2021: CVS 292.1B USD
  7. Fiscal year 2022: CVS 322.5B USD
  8. Fiscal year 2023: CVS 357.8B USD
  9. Fiscal year 2024: CVS 372.8B USD
  10. Fiscal year 2025: CVS 402.1B USD

Net margin

The net margin fell in 5 years from 2.7% to 0.4%.

CVS Sector today 13.9% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: CVS 3.0%
  2. Fiscal year 2017: CVS 3.6%
  3. Fiscal year 2018: CVS −0.3%
  4. Fiscal year 2019: CVS 2.6%
  5. Fiscal year 2020: CVS 2.7%
  6. Fiscal year 2021: CVS 2.7%
  7. Fiscal year 2022: CVS 1.3%
  8. Fiscal year 2023: CVS 2.3%
  9. Fiscal year 2024: CVS 1.2%
  10. Fiscal year 2025: CVS 0.4% · Sector today 13.9%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 2.3x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.9%
dividend per share, average per year
Coverage by free cash flow
2.3x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 2.00 USD → fiscal year 2025 2.66 USD = +5.9% per year
  • Free cash flow per share 6.14 USD ÷ dividend per share 2.66 USD = 2.3x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.66 USD · Fiscal year 2025
Dividend growth per year
3 y +6.5%5 y +5.9%10 y +6.6%
Payout ratio
of earnings 191% of free cash flow 44%
To shareholders (5 years)
24.0B USD 36% through repurchases
Share count over 5 years
−3.3% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 2.00 USD to 2.66 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.70 USD
  2. Fiscal year 2017: Dividend per share 2.00 USD
  3. Fiscal year 2018: Dividend per share 2.00 USD
  4. Fiscal year 2019: Dividend per share 2.00 USD
  5. Fiscal year 2020: Dividend per share 2.00 USD
  6. Fiscal year 2021: Dividend per share 2.00 USD
  7. Fiscal year 2022: Dividend per share 2.20 USD
  8. Fiscal year 2023: Dividend per share 2.42 USD
  9. Fiscal year 2024: Dividend per share 2.66 USD
  10. Fiscal year 2025: Dividend per share 2.66 USD

Payout ratios

The payout ratio rose in 5 years from 36.6% to 191.4%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 34.7% · Payout ratio (free cash flow) 23.5%
  2. Fiscal year 2017: Payout ratio (earnings) 31.1% · Payout ratio (free cash flow) 33.7%
  3. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) 29.8%
  4. Fiscal year 2019: Payout ratio (earnings) 39.4% · Payout ratio (free cash flow) 25.1%
  5. Fiscal year 2020: Payout ratio (earnings) 36.6% · Payout ratio (free cash flow) 19.5%
  6. Fiscal year 2021: Payout ratio (earnings) 33.6% · Payout ratio (free cash flow) 16.7%
  7. Fiscal year 2022: Payout ratio (earnings) 70.1% · Payout ratio (free cash flow) 21.6%
  8. Fiscal year 2023: Payout ratio (earnings) 37.4% · Payout ratio (free cash flow) 30.1%
  9. Fiscal year 2024: Payout ratio (earnings) 72.7% · Payout ratio (free cash flow) 53.3%
  10. Fiscal year 2025: Payout ratio (earnings) 191.4% · Payout ratio (free cash flow) 43.5%

What goes back to shareholders

Over 5 years, 24.0B USD went back to shareholders, 36% of it through share repurchases. That is 45% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 1.8B USD · Share repurchases 4.5B USD · New shares issued (including employee plans) not available · Free cash flow 7.8B USD
  2. Fiscal year 2017: Dividends paid 2.0B USD · Share repurchases 4.4B USD · New shares issued (including employee plans) not available · Free cash flow 6.1B USD
  3. Fiscal year 2018: Dividends paid 2.0B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 6.8B USD
  4. Fiscal year 2019: Dividends paid 2.6B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 10.4B USD
  5. Fiscal year 2020: Dividends paid 2.6B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 13.4B USD
  6. Fiscal year 2021: Dividends paid 2.6B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 15.7B USD
  7. Fiscal year 2022: Dividends paid 2.9B USD · Share repurchases 3.5B USD · New shares issued (including employee plans) not available · Free cash flow 13.5B USD
  8. Fiscal year 2023: Dividends paid 3.1B USD · Share repurchases 2.0B USD · New shares issued (including employee plans) not available · Free cash flow 10.4B USD
  9. Fiscal year 2024: Dividends paid 3.4B USD · Share repurchases 3.0B USD · New shares issued (including employee plans) not available · Free cash flow 6.3B USD
  10. Fiscal year 2025: Dividends paid 3.4B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 7.8B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

CVS Health next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison CVS, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health this stock 402.1B USD +8.4%–1.2%0.4%2.4%29.7%1.9%7/9
CI Cigna 274.9B USD +11.4%–3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
Median of the sector 26 symbols 44.4B USD +8.5%67.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector CVS next to MCK – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+8.4% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 8.4% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−24.4% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: −23.9% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 24.4% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

0.4% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 0.44 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 2.7%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.71 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.71 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light red: above earnings

191% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
402.1B USD
Revenue vs. prior year
+7.8%
Net income (FY)
1.8B USD
Net income vs. prior year
−61.7%
EPS (FY)
1.39 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 10, 2026 · Balance sheet Sep 30, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 402.1B1.8B 0.4% 1.39 2.66 191%
2024Dec 31, 2024 372.8B4.6B 1.2% 3.66 2.66 73%
2023Dec 31, 2023 357.8B8.3B 2.3% 6.47 2.42 37%
2022Dec 31, 2022 322.5B4.1B 1.3% 3.14 2.20 70%
2021Dec 31, 2021 292.1B7.9B 2.7% 5.95 2.00 34%
2020Dec 31, 2020 268.7B7.2B 2.7% 5.46 2.00 37%
2019Dec 31, 2019 256.8B6.6B 2.6% 5.08 2.00 39%
2018Dec 31, 2018 194.6B−594.0M −0.3% −0.57 2.00 –
2017Dec 31, 2017 184.8B6.6B 3.6% 6.44 2.00 31%
2016Dec 31, 2016 177.5B5.3B 3.0% 4.90 1.70 35%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 108.4B2.2B 2.0% 1.68 0.67 40%
Q2/26Jun 30, 2026 106.1B3.0B 2.8% 2.31 0.67 29%
Q1/26Mar 31, 2026 100.4B2.9B 2.9% 2.30 0.67 29%
Q4/25*Dec 31, 2025 105.7B2.9B 2.8% – 0.67 –
Q3/25Sep 30, 2025 102.9B−4.0B −3.9% −3.13 0.67 –
Q2/25Jun 30, 2025 98.9B1.0B 1.0% 0.80 0.67 83%
Q1/25Mar 31, 2025 94.6B1.8B 1.9% 1.41 0.67 47%
Q4/24*Dec 31, 2024 97.7B1.6B 1.7% – 0.67 –
Q3/24Sep 30, 2024 95.4B87.0M 0.1% 0.07 0.67 950%
Q2/24Jun 30, 2024 91.2B1.8B 1.9% 1.41 0.67 47%
Q1/24Mar 31, 2024 88.4B1.1B 1.3% 0.88 0.67 76%
Q4/23*Dec 31, 2023 93.8B2.0B 2.2% – 0.61 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $2.0M1 person $00 people +$2.0M
6 months $2.0M1 person $00 people +$2.0M
12 months $2.0M1 person $323.7M2 people −$321.7M

Latest transactions

  • Nov 6, 2026 Shah Prem S Officer Open-market purchase 23,855 shares · $2.0M · SEC
  • May 21, 2026 Robbins Larry Director Open-market sale 370,462 shares · $34.6M · SEC
  • May 20, 2026 Robbins Larry Director Open-market sale 800 shares · $77.0K · SEC
  • May 20, 2026 Robbins Larry Director Open-market sale 66,881 shares · $6.4M · SEC
  • May 20, 2026 Robbins Larry Director Open-market sale 152,691 shares · $14.5M · SEC
  • May 20, 2026 Robbins Larry Director Open-market sale 797,628 shares · $74.6M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold CVS Health?

All superinvestor portfolios

2 of 26 tracked superinvestors report a position.

Superinvestors with a position in CVS Health, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Renaissance Technologies 0.3% +517.7% increased Q3 2026
Bridgewater Associates 0.1% −14.2% reduced Q3 2026

Sold out in the latest quarter: Andreas Halvorsen, Paul Tudor Jones, Steve Cohen.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score -35

Price vs. EMA 50-15
Price vs. EMA 200-15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-10
Price change 60 days-15

Volatility and trend strength

ADX 14 (trend strength)moderate (20 to 25)
Price change 60 daysdown

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on CVS yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: CVS

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close